Circulating plasma lncRNAs as novel markers of EGFR mutation status and monitors of epidermal growth factor receptor‐tyrosine kinase inhibitor therapy

Circulating plasma lncRNAs as novel markers of EGFR mutation status and monitors of epidermal growth factor receptor‐tyrosine kinase inhibitor therapy

Background Epidermal growth factor receptor (EGFR) gene mutations predict tumor response to EGFR tyrosine kinase inhibitors (EGFR‐TKIs) in non‐small cell lung cancer (NSCLC). However, even patients with EGFR‐sensitive mutations in NSCLC have limited efficacy with EGFR‐TKI. Studies have shown that lo...

Full description

Bibliographic Details
Main Authors: Panpan Lv, Shaoxing Yang, Wenjing Liu, Haifeng Qin, Xiuhua Tang, Fangfang Wu, Zeyuan Liu, Hongjun Gao, Xiaoqing Liu
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Thoracic Cancer
Subjects:
Biomarker
epidermal growth factor receptor
long noncoding RNA
non‐small cell lung cancer
tyrosine kinase inhibitor
Online Access:https://doi.org/10.1111/1759-7714.13216

Internet

https://doi.org/10.1111/1759-7714.13216

Similar Items